153P A phase II study of cabozantinib in metastatic/unresectable refractory GIST from a tertiary care centre in India
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Ripretinib, the current standard fourth-line therapy in advanced gastrointestinal stromal tumours (GIST), is largely unavailable in LMICs. Cabozantinib is a multikinase inhibitor with activity against MET, VEGFR2, and KIT. This study evaluated the efficacy and safety of cabozantinib in patients with metastatic/advanced GIST who had progressed after ≥3 prior tyrosine kinase inhibitors (TKIs).
Source: ESMO rare cancers.
Institution: All India Institute of Medical Sciences
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,170
Funders: AstraZeneca, Chordoma Foundation
OpenAlex ID: W7134280806
FWCI:
Cites:
Cited by:
Related to: